We are live on ! Find out more
MAZE

Maze Therapeutics
MAZE

68 hedge funds and large institutions have $441M invested in Maze Therapeutics in 2025 Q1 according to their latest regulatory filings, with 68 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

91.45% more ownership

Funds ownership: 0% → 91.45% (+91%)

Holders
68
Holders Change
+68
Holders Change %
–
% of All Funds
0.91%
Holding in Top 10
8
Holding in Top 10 Change
+8
Holding in Top 10 Change %
% of All Funds
0.11%
New
68
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TGI
TRV GP IV
Massachusetts
+$73.1M
2
FLSM
Frazier Life Sciences Management
California
+$49.7M
3
AVM
Arch Venture Management
Illinois
+$49.6M
4
DTC
Deep Track Capital
Connecticut
+$39.4M
5
MCMC
Matrix Capital Management Company
New Hampshire
+$29.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
26
Affinity Asset Advisors
New York
$2.75M +$3.01M +250,000 New
Geode Capital Management
27
Geode Capital Management
Massachusetts
$2.34M +$2.56M +212,464 New
DCM
28
Driehaus Capital Management
Illinois
$1.45M +$1.59M +132,115 New
Alyeska Investment Group
29
Alyeska Investment Group
Illinois
$1.38M +$1.5M +125,000 New
BFM
30
Boothbay Fund Management
New York
$1.07M +$1.17M +96,968 New
UBS Group
31
UBS Group
Switzerland
$970K +$1.06M +88,064 New
Charles Schwab
32
Charles Schwab
California
$796K +$870K +72,305 New
Northern Trust
33
Northern Trust
Illinois
$780K +$853K +70,838 New
State Street
34
State Street
Massachusetts
$712K +$779K +64,713 New
GCM
35
Ghisallo Capital Management
Massachusetts
$330K +$361K +30,000 New
Morgan Stanley
36
Morgan Stanley
New York
$263K +$288K +23,893 New
Invesco
37
Invesco
Georgia
$226K +$247K +20,552 New
Citadel Advisors
38
Citadel Advisors
Florida
$220K +$241K +20,000 New
Marshall Wace
39
Marshall Wace
United Kingdom
$216K +$236K +19,597 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$190K +$207K +17,233 New
OAM
41
Oxford Asset Management
United Kingdom
$187K +$205K +17,000 New
Barclays
42
Barclays
United Kingdom
$161K +$176K +14,644 New
DKCM
43
Davidson Kempner Capital Management
New York
$151K +$165K +13,670 New
Goldman Sachs
44
Goldman Sachs
New York
$145K +$158K +13,129 New
N
45
Nuveen
North Carolina
$125K +$137K +11,375 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$117K +$128K +10,608 New
JP Morgan Chase
47
JP Morgan Chase
New York
$112K +$122K +10,141 New
Deutsche Bank
48
Deutsche Bank
Germany
$97.8K +$107K +8,885 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$79.7K +$87.1K +7,235 New
Citigroup
50
Citigroup
New York
$68.4K +$74.8K +6,216 New
1
2
3

MAZE Hedge Fund Activity: Q1 2025 in Review

68 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q1 2025, worth a combined $441M.

Buyers outnumbered sellers: 68 funds opened new MAZE positions and 0 closed out — a net gain of 68 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was TRV GP IV, opening a new position worth an estimated $73.1M.

  • 68 institutional investors held Maze Therapeutics (MAZE) as of Q1 2025, up from 0 in Q4 2024.
  • Funds reported $441M of Maze Therapeutics stock for Q1 2025.
  • 68 funds opened new Maze Therapeutics positions in Q1 2025 and 0 closed out, a net change of +68 holders.
  • The largest Maze Therapeutics buyer in Q1 2025 was TRV GP IV, an estimated $73.1M added.

Based on aggregated 13F filings for Q1 2025.